Test Tubes

Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market.

As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

Our clients range from universities and their spin-out companies through to mature biotech multinationals.

For companies looking to fund R&D or ensure the viability of their future pipeline, you will need to undertake the kinds of collaborations that have been behind many of the most successful biotech products. Through our extensive work acting for biotech organisations, we advise on the full range of collaboration and licensing agreements at all stages of product development, including R&D collaborations and commercialisation agreements.

In addition to helping you commercialise your intellectual property, we can help protect it through our knowledge of intellectual property rights enforcement .  

With products at the forefront of biomedical knowledge, the regulatory framework applicable will often be complex. We advise on the regulatory requirements applicable to tissues/cells, biological therapies, in addition to clinical trials. We also advise on pricing, reimbursement and public procurement issues on any authorised product to help ensure its profitability, even in the face of increasing pressure on pricing.

We have extensive experience advising on fundraising for start-ups along with IPOs and capital markets fundraising for developed companies, as well as public and private M&A in the sector.

High­lights of our ex­per­i­ence in Bi­otech
Roslin Bio­med (the “Dolly the Sheep” com­pany) through its li­fe­cycle and on its ac­quis­i­tion by Ge­r­on Corp.hVIVO plc on PrEP Bio­pharm Lim­ited’s li­cen­cing ar­range­ments to en­able PrEP to de­vel­op and...
Law-Now: Lifes­ci­ences
Vis­it Law-Now for leg­al know-how and com­ment­ary

Feed

04/06/2019
Fu­ture Lead­ers
We are pleased to in­vite you to the latest sem­in­ar in our 'Fu­ture Lead­ers Sem­in­ar Series' which is run by less seni­or mem­bers of our team for the be­ne­fit of ju­ni­or in-house law­yers and oth­er pro­fes­sion­als.This...
29/11/2018
(We­bin­ar) Vi­tal Signs
The UK Life Sci­ences sec­tor wel­comed Sir John Bell’s Life Sci­ences In­dus­tri­al Strategy last year. Its bold vis­ion and am­bi­tion have the po­ten­tial to drive a new era of growth. But as a new sur­vey by...
19/09/2018
Fu­ture Lead­ers Sem­in­ar Series
We are pleased to an­nounce the third sem­in­ar in our 'Fu­ture Lead­ers Sem­in­ar Series' which is run by less seni­or mem­bers of our team for the be­ne­fit of ju­ni­or in-house law­yers and oth­er pro­fes­sion­als...
20/06/2018
In­nov­a­tion in the Cloud - Re­du­cing IP Risk for the Life Sci­ences and Health­care...
New tech­no­lo­gies like cloud com­put­ing are trans­form­ing the Life Sci­ences in­dustry. Many busi­nesses now in­cor­por­ate data ana­lyt­ics and soft­ware de­vel­op­ment in­to their core op­er­a­tions. In the pro­cess, health­care...
21/06/2017
Lifes­ci­ences We­binars: Spring Series 2017
We are de­lighted to in­vite you to the Spring We­bin­ar Series hos­ted by the CMS Lifes­ci­ences Sec­tor Group.The series has been de­signed to give you and your col­leagues an over­view of the leg­al as­pects of...
21/06/2017
Lifes­ci­ences We­binars: Spring Series 2017
We are de­lighted to in­vite you to the Spring We­bin­ar Series hos­ted by the CMS Lifes­ci­ences Sec­tor Group.The series has been de­signed to give you and your col­leagues an over­view of the leg­al as­pects of...
11/05/2017
Lifes­ci­ences We­binars: Spring Series 2017
We are de­lighted to in­vite you to the Spring We­bin­ar Series hos­ted by the CMS Lifes­ci­ences Sec­tor Group.The series has been de­signed to give you and your col­leagues an over­view of the leg­al as­pects of...